Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Cyramza® (ramucirumab): Administration - Information on filter and infusion line usage
Administer via infusion pump. A separate infusion line with a protein-sparing 0.22-micron filter must be used for the infusion and the line must be flushed with sodium chloride 9 mg/ml (0.9%) solution for injection at the end of the infusion.
Administration using a protein-sparing filter
The filter is recommended to remove any possible particles (which include micro-organisms) that may have been inadvertently introduced during the preparation for infusion.
Ramucirumab is compatible with a 0.2 micron protein sparing (low protein binding) filter of at least 4.2 cm2 surface area.1
Can the same filter be used when Cyramza is administered with another treatment?
In clinical studies, when ramucirumab was administered in combination with another treatment, the filter was changed between the administration of ramucirumab and the administration of other products.1 Please refer to the local labeling for other products for details on administration.
Administration using the same infusion line
It is acceptable to use a single/same intravenous (IV) line to administer ramucirumab either before, or after, another medication if the infusion line used is properly flushed with normal saline prior to administering the ramucirumab through the same line.1
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 24 March 2022